Qiagen and Celera establish distribution agreement for respiratory pathogen panel
Qiagen and Celera have announced an agreement under which Qiagen will distribute a Celera molecular multiplex assay. The assay is the next generation version of Qiagen’s ResPlex II assay for detection of respiratory pathogens. Multiplex assays allow testing for a multiple number of different pathogens in a single run.
Under the terms of the agreement, Qiagen has the exclusive worldwide rights to distribute this multiplex test kit, which will be manufactured by Celera. The ResPlex assay detects 19 different pathogens associated with respiratory infections and is designed for use with LiquiChip (Luminex) 100 and 200 instrument platforms.
The new ResPlex kits will be available through Qiagen’s existing sales channels. The new test will be submitted for regulatory approval in the United States and Europe.
7th edition of STEM Equity Monitor now available
The latest national data resource on diversity in STEM has new design features intended to...
Professor Girish Dwivedi wins 2026 WA Pearcey Entrepreneur of the Year Award
As part of the 35th annual WAITTA INCITE Awards, Dwivedi was recognised for his contribution to...
Monash University signs MOU with TGA Academic Outreach Program
The program fosters collaboration across research, knowledge exchange and education to support...
